Liang Xu
University of Kansas Cancer Center, USA
Biography
Dr. Liang Xu did post-doc training at Stanford University and started his own lab at University of Michigan working on cancer drug discovery. He is a co-inventor of the first natural product Bcl-2 inhibitor that entered into clinical trials. He has >25 patents with four INDs in advanced clinical trials. He is a Professor of Cancer Biology at University of Kansas and has been funded by NIH, DOD and Komen Foundation. He is now working on cancer drug discovery targeting the so far undruggable oncoproteins such as RNA-binding proteins.
Abstract
Abstract : Natural products targeting RNA-binding protein Musashi
Speaker Presentations
Speaker PPTs Click Here